Lannett launches generic AggrenoxAspirin and extended-release dipyridamole capsules had a market value of roughly $158 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower. ANI acquires Coeptis' pipeline of development stage genericsANI Pharmaceuticals has acquired Coeptis Pharmaceutical's pipeline of seven development stage generic products. Amgen, Allergan get FDA nod for biosimilar Herceptin The FDA approval of biosimilar Herceptin provides an additional treatment option for patients across three types of cancer. Teva introduces generic Albenza Teva's generic Albenza tablets are available in a dosage strength of 200 mg, in bottles of two tablets. Lupin taps Sunil Makharia as interim CFO Lupin has named an interim CFO while in the process of selecting a permanent candidate for the position. Fresenius Kabi launches ready to administer Neostigmine methylsulfate injection Fresenius Kabi is expanding its Simplist prefilled syringe portfolio with its fourth new product in a year. Hikma launches generic Tracleer Tracleer (bosentan) had a market value of $268 million in 2018. Alembic gets FDA OK for generic Sinemet Carbidopa and levodopa extended-release tablets had a market value of roughly $24 million for the 12 months ended December 2018. Novitium launches generic Revatio Revatio for oral suspension, 10mg/ml, had a market value of about $200 million for the 12 months ended March 2019. AAM opposes changes to exclusivity in proposed bill The Association for Accessible Medicines will oppose The Lower Health Care Costs Act without changes to the discussion draft, CEO Chip Davis told the Senate HELP Committee in a recent letter. First Previous 169 170 171 172 173 Next Last